Skip to main
NBP

NovaBridge Biosciences (NBP) Stock Forecast & Price Target

NovaBridge Biosciences (NBP) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

NovaBridge Biosciences is well-positioned for future growth as its innovative immuno-oncology pipeline and core product, givastomig, show promise in clinical trials. The company's strong financials, including a decreased equity in loss and net loss from continuing operations, as well as a high number of issued and outstanding shares, indicate a solid foundation for future success. With plans for a global Phase 3 program and potential accelerated approval eligibility, NovaBridge has the potential to be a strong contender in the anti-VEGF landscape and expand its market reach with givastomig's ability to target low-level CLDN18.2 expressed in gastric cancer patients. There are still questions regarding givastomig's durability and how it compares to other CLDN18.2-targeting drugs, but the recent Phase 2a data and management's emphasis on durability and ease of integration into standard treatment protocols suggest a positive outlook for NovaBridge Biosciences.

Bears say

NovaBridge Biosciences is facing several challenges in the biotechnology market, including a highly competitive landscape and the need for significant investment in clinical trials for their pipeline drugs such as givastomig, uliledlimab, and ragistomig. Additionally, the company has yet to generate any significant revenue, putting pressure on their financials in the short term. Furthermore, there are concerns about the durability of givastomig's effects, which could limit its adoption and market share potential. These factors, combined with potential ownership changes and a lack of commercialization experience, lead to a negative outlook on NovaBridge Biosciences's stock.

NovaBridge Biosciences (NBP) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of NovaBridge Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About NovaBridge Biosciences (NBP) Forecast

Analysts have given NovaBridge Biosciences (NBP) a Strong Buy based on their latest research and market trends.

According to 1 analysts, NovaBridge Biosciences (NBP) has a Strong Buy consensus rating as of May 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

NovaBridge Biosciences (NBP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.